Investor Relations  ·  Nasdaq: ELOX

A precision approach to rare kidney disease

Investor materials, SEC filings, and contact information are available below.

Company Overview

Clinical-stage biopharmaceutical company advancing exaluren for rare kidney diseases caused by nonsense mutations. Active Phase 2b study in nonsense mutation Alport syndrome (NMAS). Program in development for NM-ADPKD. Listed on Nasdaq: ELOX.

SEC Filings

Annual reports, quarterly filings, and other SEC documents are available through the SEC EDGAR database.

Governance Documents

Eloxx is committed to strong corporate governance. The following Board committee charters and governance policies are available for review.

Audit Committee Charter (PDF) → Compensation Committee Charter (PDF) → Nominating & Corporate Governance Committee Charter (PDF) → Code of Business Conduct and Ethics (PDF) →

Investor Contact

For investor relations inquiries, analyst requests, or to be added to our mailing list, please contact us directly.

Forward-Looking Statements. This website contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, regarding Eloxx Pharmaceuticals and its product candidates, including exaluren. These statements involve known and unknown risks and uncertainties, including those related to clinical development timelines, regulatory processes, and capital requirements. Actual results may differ materially. Eloxx undertakes no obligation to update forward-looking statements after the date hereof.